BackgroundE-mental health holds promise for people with severe mental illness, but has a limited evidence base. This study explored the effect of e-health added to face-to-face delivery of the Illness Management and Recovery Programme (e-IMR).MethodIn this multi-centre exploratory cluster randomized controlled trial, seven clusters (n = 60; 41 in intervention group and 19 in control group) were randomly assigned to e-IMR + IMR or IMR only. Outcomes of illness management, self-management, recovery, symptoms, quality of life, and general health were measured at baseline (T0), halfway (T1), and at twelve months (T2). The data were analysed using mixed model for repeated measurements in four models: in 1) we included fixed main effects for time trend and group, in 2) we controlled for confounding effects, in 3) we controlled for interaction effects, and in 4) we performed sub-group analyses within the intervention group.ResultsNotwithstanding low activity on e-IMR, significant effects were present in model 1 analyses for self-management (p = .01) and recovery (p = .02) at T1, and for general health perception (p = .02) at T2, all in favour of the intervention group. In model 2, the confounding covariate gender explained the effects at T1 and T2, except for self-management. In model 3, the interacting covariate non-completer explained the effects for self-management (p = .03) at T1. In model 4, the sub-group analyses of e-IMR-users versus non-users showed no differences in effect.ConclusionBecause of confounding and interaction modifications, effectiveness of e-IMR cannot be concluded. Low use of e-health precludes definite conclusions on its potential efficacy. Low use of e-IMR calls for a thorough process evaluation of the intervention.
MULTIFILE
Objective To evaluate the validity and reliability of the Dutch STarT MSK tool in patients with musculoskeletal pain in primary care physiotherapy. Methods Physiotherapists included patients with musculoskeletal pain, aged 18 years or older. Patients completed a questionnaire at baseline and follow-up at 5 days and 3 months, respectively. Construct validity was assessed by comparing scores of STarT MSK items with reference questionnaires. Pearson’s correlation coefficients were calculated to test predefined hypotheses. Test-retest reliability was evaluated by calculating quadratic-weighted kappa coefficients for overall STarT MSK tool scores (range 0–12) and prognostic subgroups (low, medium and high risk). Predictive validity was assessed by calculating relative risk ratios for moderate risk and high risk, both compared with low risk, in their ability to predict persisting disability at 3 months. Results In total, 142 patients were included in the analysis. At baseline, 74 patients (52.1%) were categorised as low risk, 64 (45.1%) as medium risk and 4 (2.8%) as high risk. For construct validity, nine of the eleven predefined hypotheses were confirmed. For test-retest reliability, kappa coefficients for the overall tool scores and prognostic subgroups were 0.71 and 0.65, respectively. For predictive validity, relative risk ratios for persisting disability were 2.19 (95% CI: 1.10–4.38) for the medium-risk group and 7.30 (95% CI: 4.11–12.98) for the highrisk group. Conclusion The Dutch STarT MSK tool showed a sufficient to good validity and reliability in patients with musculoskeletal pain in primary care physiotherapy. The sample size for high-risk patients was small (n = 4), which may limit the generalisability of findings for this group. An external validation study with a larger sample of high-risk patients (�50) is recommended.
Deze publicatie presenteert de resultaten van het Smartest Connected Cargo Airport Schiphol (SCCAS)-project: een tweejarig onderzoek naar logistieke innovaties die de concurrentiepositie van Schiphol op de luchtvrachtketen versterken. In dit project hebben KLM Cargo, Schiphol Nederland, Cargonaut, TU Delft en Hogeschool van Amsterdam samen met diverse partijen in de luchtvrachtketen nieuwe inzichten ontwikkeld om het afhandelingsproces op Schiphol te stroomlijnen en de productkwaliteit in temperatuurgevoelige ketens zoals bloemen en farma beter te beheersen.In Europa heeft Schiphol een sterke positie: het is de derde vrachtluchthaven na Frankfurt en Parijs. Door de beperking van het aantal beschikbare slots op Schiphol krijgen andere luchthavens zoals Brussel, Luik en Luxemburg de kans om extra lading aan te trekken. Het is daarom de ambitie van Schiphol zich te ontwikkelen tot de Europese voorkeursluchthaven voor logistiek hoogwaardige goederenstromen zoals e-commerce, farmaceutische producten en bloemen, en zich te onderscheiden door een efficiënt en betrouwbaar afhandelingsproces. Om die positie te bereiken zet Schiphol in op vier concrete innovatiedoelstellingen:- verbetering van transparantie in de keten door het delen van informatie;- inzicht in logistieke prestaties op basis van volledige en betrouwbare data over zendingen;- efficiënte en betrouwbare aan- en afvoer van luchtvrachtzendingen (landside pickup & delivery);- procesverbeteringen in de supply chains van temperatuurgevoelige producten.